BSF Enterprise PLC
23 September 2026
23 September 2026
BSF Enterprise PLC
("BSF" or the "Company")
Key US Patent for ETSYL® Technology
BSF Enterprise Plc (LSE: BSFA), (OTCQB: BSFAF), the biotechnology company focused on developing tissue engineering, lab-grown materials, and bioactive solutions, is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for US Patent Application No. 17/782,948, entitled "Collagen Production", held by the Company's 100% owned subsidiary, 3D Bio-Tissues Ltd ("3DBT").
A Notice of Allowance represents the formal conclusion of substantive examination by the USPTO, confirming that the patent claims meet all statutory requirements for novelty, inventive step, and patentability. The allowed claims protect proprietary methods for utilising the bioactive peptide ETSYL® (palmitoyl pentapeptide-87) to stimulate and enhance collagen production in cells.
Following payment of the standard administrative issue fee ahead of the December 2026 statutory deadline, the US Patent will proceed to formal issuance and registration.
Strategic & Commercial Highlights:
● Securing the US Market: The United States represents the single largest commercial market globally for anti-ageing skincare, dermocosmetics, and bioactive peptide formulations. The Patent secures a defensible intellectual property moat across North America.
● Commercial Reinforcement for Global Partnerships: The Patent directly underpins the worldwide exclusive commercialisation and supply agreement executed with SCHAKAU Managementberatung GmbH ("SCHAKAU") for ETSYL® in cosmetics and luxury beauty, providing long-term patent backing for downstream product sales and third-party licensing.
● Dual-Market Application: Originally developed within 3DBT's tissue-engineering research to accelerate natural collagen synthesis in lab-grown structures, this Patent confirms the platform's cross-sector commercial applicability within high-value cosmetic actives.
Executive Commentary:
Che Connon, Chief Executive Officer of BSF Enterprise PLC, commented:
"Securing a Notice of Allowance from the USPTO is an important validation of the platform science developed by our team at 3D Bio-Tissues. The United States is a critical commercial jurisdiction for bioactive compounds, and having our core collagen-boosting mechanism formally allowed establishes a robust intellectual property foundation.
This allowance directly supports our commercial strategy for ETSYL®. Having recently partnered with SCHAKAU to launch ETSYL® into the global luxury skincare and cosmetics sector, this US patent protection enhances the long-term commercial value of our supply arrangements and provides our commercial partners with verified intellectual property exclusivity in the world's largest consumer beauty market."
This announcement contains inside information for the purposes of Article 7 of Regulation 2014/596/EU which is part of domestic UK law pursuant to the Market Abuse (Amendment) (EU Exit) regulations (SI 2019/310).
Engage with the BSF Enterprise management team directly by asking questions, watching video
summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor
website here: https://bsfenterprise.com/link/P2xjme
For further enquiries, please visit www.bsfenterprise.com or contact:
|
BSF Enterprise PLC Geoff Baker - Chairman Che Connon - CEO & Director We encourage all investors to share questions on this announcement via our investor website. |
|
|
Bowsprit Partners John Treacy James Sheehan |
+44 (0)203 883 4430 |
|
ISIN of the Ordinary Shares is GB00BHNBDQ51. SEDOL Code is BHNBDQ5. |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.